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n Analysis of the ACUITY (Acute Catheterization and Urgent Intervention
riage strategY) Trial
. Michael Lincoff, MD,* Steven R. Steinhubl, MD,†,‡ Steven V. Manoukian, MD,§
erek Chew, MD, Charles V. Pollack, JR, MD,¶ Frederick Feit, MD,# James H. Ware, PHD,**
ichel E. Bertrand, MD,†† E. Magnus Ohman, MD,‡‡ Walter Desmet, MD,§§
avid A. Cox, MD, Roxana Mehran, MD,¶¶ Gregg W. Stone, MD,¶¶
or the ACUITY of Trial Investigators*
leveland, Ohio; Danville, Philadelphia, and Allentown, Pennsylvania; Parsippany, New Jersey;
ashville, Tennessee; Adelaide, Australia; New York, New York; Boston, Massachusetts; Lille,
rance; Durham, North Carolina; and Leuven, Belgium
bjectives This study sought to determine if the efﬁcacy of bivalirudin alone versus heparin plus a
lycoprotein (GP) IIb/IIIa inhibitor is dependent upon the duration of clopidogrel pre-treatment in
atients undergoing percutaneous coronary intervention (PCI) in the ACUITY (Acute Catheterization
nd Urgent Intervention Triage strategY) trial.
ackground The administration of a clopidogrel loading dose several hours before PCI reduces the
isk of periprocedural thrombotic events.
ethods Patients with an acute coronary syndrome were randomized to heparin plus a GP IIb/IIIa
nhibitor (control), bivalirudin plus a GP IIb/IIIa inhibitor, or bivalirudin alone. Dose and timing of
lopidogrel were left to the investigator’s discretion.
esults Of 13,819 patients randomized, 7,789 underwent PCI. When clopidogrel was initiated at any
ime before angiography or within 30 min after PCI, randomization to bivalirudin alone (n  2,284)
r control (n  2,189) was associated with similar ischemic outcomes (8.2% vs. 8.3%, risk ratio: 0.98,
5% conﬁdence interval: 0.81 to 1.20). Those patients who received clopidogrel 30 min after PCI
r not at all experienced an increase in ischemic events when randomized to bivalirudin alone (n 
90) versus control (n  317) (14.1% vs. 8.5%, risk ratio: 1.66, 95% conﬁdence interval: 1.05 to 2.63).
ajor bleeding was signiﬁcantly less frequent in patients treated with bivalirudin alone.
onclusions This post-hoc analysis suggests that in acute coronary syndrome patients, as long as
lopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is simi-
arly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with sig-
iﬁcantly less bleeding. If it is anticipated that clopidogrel will be given late or not at all after PCI,
ivalirudin alone may be associated with worse ischemic outcomes. (Comparison of Angiomax Ver-
us Heparin in Acute Coronary Syndromes; NCT00093158) (J Am Coll Cardiol Intv 2008;1:639–48)
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Clopidogrel in ACUITY
640he administration of clopidogrel before percutaneous cor-
nary intervention (PCI), typically as a loading dose of at
east 300 mg, has been found in a wide variety of studies to
ecrease the incidence of periprocedural thrombotic events
1). In the majority of these studies, adjunctive antithrom-
otic therapy has included aspirin and unfractionated hep-
rin (UFH) with or without a glycoprotein (GP) IIb/IIIa
eceptor inhibitor. There are theoretical reasons why ad-
unctive antithrombotic therapy may influence the benefit of
lopidogrel pre-treatment. For example, because unfrac-
ionated heparin (2) and even platelet GP IIb/IIIa antago-
ists (3) may increase platelet activation, inhibition of
latelet activation with clopidogrel may be of particular
enefit in patients receiving UFH with or without a GP
Ib/IIIa antagonist. Alternatively, because the direct throm-
in inhibitor bivalirudin does not directly inhibit platelet
ggregation as do the GP IIb/IIIa inhibitors, additional
pecific antiplatelet protection may be advantageous in
atients receiving only bivalirudin. This may be particularly
rue in a troponin-positive acute coronary syndrome (ACS)
patient, in whom the addition of
a GP IIb/IIIa inhibitor has been
shown to be most beneficial (4).
Previous analysis of a large
randomized trial among patients
undergoing nonurgent PCI
found that bivalirudin was not
inferior to heparin plus a GP
IIb/IIIa inhibitor in reducing
ischemic events and that the ef-
ficacy of bivalirudin was not in-
fluenced by the timing of clopi-
dogrel administration (5). In
contrast, preliminary analysis of
he ACUITY (Acute Catheterization and Urgent Interven-
ion Triage strategY) trial found an interaction of borderline
ignificance (p  0.054) between clopidogrel exposure and
andomized therapy on the incidence of 30-day composite
rom the *Cleveland Clinic Foundation, Cleveland, Ohio; †Geisinger Clinic,
anville, Pennsylvania; ‡The Medicines Company, Parsippany, New Jersey; §The
arah Cannon Research Institute and The Centennial Heart Center, Nashville,
ennessee; Flinders Medical Center, Adelaide, Australia; ¶Pennsylvania Hospital,
niversity of Pennsylvania, Philadelphia, Pennsylvania; #New York University School
f Medicine, New York, New York; **Harvard University, Boston, Massachusetts;
†Hopital Cardiologique, Lille, France; ‡‡Duke University Medical Center,
urham, North Carolina; §§University Hospital Gasthuisberg, Leuven, Belgium;
Lehigh Valley Hospital, Allentown, Pennsylvania; ¶¶Columbia University Medical
enter and the Cardiovascular Research Foundation, New York, New York. Funded
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esearch grants from the Medicines Company and Sanofi-Aventis. Dr. Steinhubl is an
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edicines Company, Sanofi-Aventis, and Schering-Plough; is a member of the 2schemia, leading to the suggestion that the use of bivaliru-
in monotherapy should be limited to those non–
T-segment elevation (NSTE) ACS patients in whom
lopidogrel pre-treatment is given (6–8).
In this post-hoc analysis of the ACUITY trial, we
pecifically evaluated the timing of the initiation of clopi-
ogrel treatment in patients undergoing PCI to determine
hether clopidogrel pre-treatment is especially beneficial or
ecessary in patients not receiving a GP IIb/IIIa antagonist.
ethods
tudy design and patients. The design of the ACUITY trial
as been previously described in detail (9,10). In brief,
atients with symptoms of unstable angina lasting 10 min
ithin the preceding 24 h were eligible if 1 or more of the
ollowing criteria were met: new ST-segment depression or
ransient elevation 1 mm; troponin I, T, or creatine
inase-myocardial band elevation; known coronary artery
isease; or all 4 other Thrombolysis In Myocardial Infarc-
ion (TIMI) unstable angina risk criteria (11). The overall
tudy population was therefore composed of patients with
STE ACS who were at moderate-to-high ischemic risk.
ajor exclusion criteria included acute ST-segment eleva-
ion myocardial infarction or shock; bleeding diathesis or
ajor bleeding episode within 2 weeks; thrombocytopenia;
alculated creatinine clearance 30 ml/min; recent admin-
stration of abciximab, warfarin, fondaparinux, fibrinolytic
gents, bivalirudin or 2 or more doses of low molecular
eight heparin; and allergy to study drugs or iodinated
ontrast that could not be adequately pre-medicated. The
tudy was approved by the institutional review board or
thics committee at each participating center, and all pa-
ients provided written, informed consent.
andomization and study medications. Telephone random-
zation was stratified by site and the prior use or intent to
dminister a thienopyridine before angiography. Patients
ere assigned in a 1:1:1 ratio to 1 of 3 antithrombin
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641egimens started immediately after randomization: heparin
either unfractionated or enoxaparin) plus a GP IIb/IIIa
nhibitor (the control group), bivalirudin plus a GP IIb/IIIa
nhibitor, or bivalirudin alone. Unfractionated heparin was
dministered as an intravenous (IV) bolus of 60 interna-
ional units (IU)/kg plus infusion of 12 IU/kg/h to target an
ctivated partial thromboplastin time of 50 to 75 s before
ngiography and an activated clotting time of 200 to 250 s
uring PCI. Enoxaparin 1 mg/kg subcutaneously every 12 h
as administered before angiography, with an additional 0.3
g/kg or 0.75 mg/kg IV bolus administered before PCI if
he most recent subcutaneous dose had been given more
han 8 or 16 h earlier, respectively. Bivalirudin was initiated
ith an IV bolus of 0.1 mg/kg and an infusion of 0.25
g/kg/h. Before PCI an additional bivalirudin IV bolus of
.5 mg/kg was administered, and the infusion was increased
o 1.75 mg/kg/h. Bivalirudin, UFH, and enoxaparin were
outinely discontinued per protocol at the completion of
ngiography or PCI. Provisional GP IIb/IIIa antagonist use
as permitted in patients randomized to bivalirudin mono-
herapy for severe breakthrough ischemia or procedural
omplications during PCI.
Angiography was performed by protocol within 72 h after
andomization, after which the decision was made regarding
reatment with PCI versus surgical or further medical
anagement. This analysis considers only patients who
nderwent PCI. Aspirin 300 to 325 mg orally or 250 to 500
g IV was administered daily during the hospitalization.
lopidogrel treatment. The initial dosing and timing of
lopidogrel were left to the investigator’s discretion per local
tandards, though a 300-mg loading dose was recom-
ended no later than 2 h after completing PCI in all
atients per protocol. Clopidogrel 75 mg daily was recom-
ended for 1 year in all patients after PCI.
Data regarding timing of clopidogrel administration were
ecorded in the case report form. Timing of the initiation of
lopidogrel treatment was based on the earliest exposure as
ocumented on the case report form For this analysis,
lopidogrel pre-treatment was prospectively categorized as:
) pre-angiography, which was further categorized as: a)
re-hospital—received before presentation to the random-
zation hospital, b) pre-randomization—received pre-
andomization but at the randomization hospital, or c)
ost-randomization, pre-angiography—received after study
andomization and before angiography; 2) peri-PCI—
nitiated after angiography and either before or within 30
in (determined a priori to reflect loading in the catheter-
zation laboratory) after PCI; or 3) post-PCI—initiated
30 min after PCI. Patients who did not receive clopi-
ogrel at any time before or after PCI were classified as
eceiving no clopidogrel. Only in patients who initially
eceived clopidogrel after randomization (44% of
lopidogrel-treated PCI patients) was the precise dose and piming of clopidogrel initiation documented. Patients who
eceived ticlopidine were excluded from this analysis.
nd points and statistical methods. The primary 30-day
fficacy end point for this analysis was composite ischemia
death from any cause, myocardial infarction, or unplanned
evascularization for ischemia) end point. Composite isch-
mia was also measured at 1 year. Major bleeding (not
elated to a coronary artery bypass graft) at 30 days as
efined in the study protocol was also evaluated as the
rincipal safety end point; bleeding events beyond 30 days
ere not measured. The component definitions of the
rimary end points have been previously detailed (12). A
linical events committee blinded to treatment assignment
djudicated all primary end point events.
Categorical variables were compared by chi-square test.
ontinuous variables were compared by the nonparametric
ilcoxon rank sum test. All primary categorical binary
vent rate analyses were performed in the intention-to-treat
opulation, with patients lost to follow-up (23 of 13,819
atients, 0.17%) included in the denominator and consid-
red nonevents. A secondary analysis was performed using
ime-to-event data (for which patients were censored at the
ime of study withdrawal or at last follow-up) displayed
sing Kaplan-Meier methodology and compared with the
og-rank test.
To explore the relationship between the time from
lopidogrel initiation to PCI and composite ischemia, the
0-day rate of composite ischemia was converted to the
ogarithmic odds so that a linear regression model could be
t using a spline transformation. All statistical analyses were
erformed by SAS software, version 8.2 (SAS Institute Inc.,
ary, North Carolina).
esults
f the entire 13,819 patients enrolled in the ACUITY trial,
,789 underwent PCI during the index hospitalization.
xposure to clopidogrel was documented in 97% (n 
,517) of all patients undergoing PCI. Overall, 5,131
atients received clopidogrel pre-angiography (pre-hospital
pre-randomization  post-randomization and pre-
ngiography), and 1,572 patients first received it peri-PCI
Fig. 1). Only 814 patients had clopidogrel initiated 30
in after the end of the PCI procedure and 129 never
eceived clopidogrel.
schemic outcomes. Among all patients combined, initiat-
ng clopidogrel in the pre-angiography versus peri-PCI
eriod was associated with similar 30-day composite isch-
mic event rates (8.6% vs. 8.3%, respectively, p  0.78). In
ontrast, compared with these 2 groups combined, 30-day
omposite ischemic event rates were significantly higher
mong those in whom clopidogrel was initiated only in the
ost-PCI period (10.6%, p 0.049) and markedly higher in
t
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642hose in whom clopidogrel was never started (17.1%, p 
.001).
Outcome with regard to the composite ischemic end point
ccording to the timing of clopidogrel initiation and random-
zation arm is illustrated in Figure 2. For patients in whom the
rst dose of clopidogrel was administered pre-angiography or
eri-PCI, there were no differences in the incidence of the
schemic end point among the 3 randomized treatment arms.
hen the first dose of clopidogrel was given more than 30 min
fter PCI (post-PCI), there was no difference in outcomes
mong those who had received heparin with a GP IIb/IIIa
nhibitor (p  0.13). Among patients who never received
lopidogrel, a numerically higher ischemic event rate that
Figure 1. Study Population
Flow diagram of all ACUITY patients and identiﬁcation of those included in thi
who had clopidogrel initiated post-randomization was the dose and time knowpproached significance (10% absolute increased, p  0.08) 3as observed in the bivalirudin-alone arm compared with the
eparin plus GP IIb/IIIa inhibitor arm.
To increase the power to evaluate specifically whether
atients not receiving a GP IIb/IIIa antagonist are
articularly dependent upon clopidogrel treatment pre-
CI, patients in the pooled GP IIb/IIIa inhibitor arms
heparin/enoxaparin or bivalirudin) were compared with
hose randomized to bivalirudin monotherapy. Ischemic
vent rates were similar among patients in whom clopi-
ogrel was initiated in the pre-angiography or peri-PCI
eriod with either bivalirudin monotherapy or a GP
Ib/IIIa inhibitor-based regimen (Fig. 3). However,
mong patients in whom clopidogrel was initiated beyond
ysis, broken down by their earliest exposure to clopidogrel. Only in patients
I  percutaneous coronary intervention.s anal0 min after PCI or not at all, event rates tended to be
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643igher in patients randomized to bivalirudin alone, al-
hough differences did not reach statistical significance.
oreover, given the small number of patients in these
atter 2 subgroups, significant imbalances in baseline and
rocedural characteristics existed (Table 1).
The benefit of clopidogrel treatment before PCI in
lacebo-controlled trials has been shown to be time-
ependent (13). To further explore the association be-
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Figure 2. 30-Day Composite Ischemic Outcomes by Randomized Treatment
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he ACUITY trial, the relationship between ischemic
vent rates and time of initiation was evaluated with time
s a continuous variable. Among the 928 patients in
hom the actual time between clopidogrel initiation and
ngiography was known (those treated after randomiza-
ion), a spline transformation of the logarithmic odds of
he ischemic end point was performed with the duration
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644f treatment as a continuous function (Fig. 4). Greater
urations of pre-treatment were not associated with
mproved rates of ischemic events, irrespective of ran-
omized therapy.
In a post-hoc analysis, when only those patients who
eceived clopidogrel either in the pre-angiography or
eri-PCI period were analyzed in combination, no sig-
ificant differences were found between randomized ther-
pies in the 30-day or 1-year composite ischemic end
oints or their components (Table 2). Alternatively,
atients in whom clopidogrel loading was delayed or
eglected experienced a significantly higher incidence of
he 30-day composite ischemic end point as well as the
ndividual component of myocardial infarction (p value
or interaction 0.32). However, there was no difference in
he combined ischemic end point or mortality at 1 year
Table 3).
leeding outcomes. Regardless of the timing of clopidogrel
nitiation, major bleeding events were significantly de-
reased in patients randomized to bivalirudin alone, with
elative reductions of 50% compared with bleeding events
Table 1. Baseline and Procedural Characteristics of Patients in Whom Clop
Clopidogrel Pre-Angiography or Per
Heparin or Bivalirudin
 GP IIb/IIIa
Inhibitor
(n  4,419)
Bivalirudin
Alone
(n  2,284)
Age, median [range], yrs 63.0 [21, 91] 62.0 [30, 92]
Age 65 45.7% 43.6%
Female 27.0% 26.2%
Diabetes 27.1% 27.3%
Hypertension 65.8% 65.5%
Hyperlipidemia 56.4% 56.3%
Current smoker 30.6% 31.1%
Prior myocardial infarction 30.0% 31.1%
Prior PCI 38.4% 40.2%
Prior coronary artery bypass
graft surgery
17.2% 18.0%
Weight, median [IQR], kg 84.0 [73.0, 95.3] 84.0 [75.0, 95.3]
Renal insufﬁciency* 19.0% 17.6%
Baseline cardiac biomarker
elevation†
64.4% 66.0%
Attempted vessels per
patient
1 83.3% 84.5%
2 14.9% 13.9%
3 1.8% 1.5%
Stent implanted—any 92.5% 92.4%
Thrombectomy or
atherectomy
2.3% 2.3%
*Calculated creatinine clearance using the Cockcroft-Gault equation60ml/min. There were no sig
normal (ULN). If troponin was not available then creatine kinase-myocardial band above the ULN w
GP glycoprotein; IQR interquartile range; PCI percutaneous coronary intervention.idogrel Was Initiated Post-PCI or Not at All
i-PCI Clopidogrel >30 min After PCI or No Clopidogrel
p Value
Heparin or Bivalirudin
 GP IIb/IIIa
Inhibitor
(n  653 )
Bivalirudin
Alone
(n  290) p Value
0.17 62.0 [32, 95] 64.0 [35, 92] 0.01
0.10 40.0% 49.3% 0.01
0.51 26.8% 31.0% 0.18
0.89 30.2% 30.9% 0.84
0.80 62.5% 65.4% 0.39
0.92 53.0% 52.5% 0.88
0.63 33.6% 29.8% 0.25
0.34 30.2% 29.8% 0.92
0.16 34.6% 34.8% 0.94
0.41 17.5% 15.5% 0.46
0.07 85.0 [75.0, 97.6] 83.76 [74.0, 96.0] 0.10
0.19 16.5% 19.0% 0.36
0.21 64.9% 68.5% 0.30
0.44
84.7% 80.9%
13.9% 17.7%
1.2% 1.4%
0.88 87.7% 88.3% 0.82
0.88 2.0% 2.4% 0.68
nificant differences between groups. †Defined as baseline troponin above local laboratories upper limit of
as used.n the control arm (Tables 2 and 3).Estimated Spline Transformation and 95% C.I.
Log Odds 
for
Composite
Ischemia
(30-Days)
Duration of Clopidogrel Treatment Prior 
to PCI (hours)
-4
-3
-2
-1
0
1
2
0 2 4 6 8 10 12 14 16 18 20 22 24
GPIIb/IIIa antagonist + any anticoagulant
Bivalirudin alone 
Figure 4. 30-Day Composite Ischemic Outcomes by Duration of
Clopidogrel Pre-Treatment
Spline transformation with 95% conﬁdence intervals (CI) of the logarithmic
odds of the composite ischemic end point at 30 days based on time of
initiation of clopidogrel treatment before PCI. The 928 patients in whom
the dose and timing of clopidogrel initiation before PCI was known are
divided into those randomized to bivalirudin alone or to a GP IIb/IIIa recep-
tor antagonist. Abbreviations as in Figures 1 and 2.
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645roponin-positive patients. When the subset of patients who
ere troponin-positive at the time of randomization were
valuated for the influence of the timing of clopidogrel treat-
ent and randomization to bivalirudin alone or combination
reatment with a GP IIb/IIIa antagonist (with heparin or
ivalirudin), the results were concordant with the overall
esults. Among troponin-positive patients who received clop-
Table 2. 30-Day and 1-Year Risk Ratios for the Composite Ischemic End P
Before or Up to 30 Min After PCI
Arm A UFH/Enox
GP IIb/IIIa Inhibitor
(n  2,189)
%
Arm B Biva
GP IIb/IIIa
(n  2,2
%
30-day
Composite ischemia* 8.3 9.0
Death 0.8 1.1
MI 5.8 6.4
Unplanned revascularization 3.3 3.7
Major bleeding 6.6 7.8
1-year
Composite ischemia* 17.9 19.7
Death 3.0 3.2
*Death, myocardial infarction (MI), or unplanned ischemia-driven revascularization.
CI confidence intervals; Enox enoxaparin; UFH unfractionated heparin; other abbreviation
Table 3. 30-Day and 1-Year Risk Ratios for the Composite Ischemic End P
PCI or Not at All
Arm A UFH/Enox
GP IIb/IIIa Inhibitor
(n  317)
%
Arm B Biva
GP IIb/IIIa
(n  3
%
30-day
Composite ischemia* 8.5 11.9
Death 1.9 1.2
MI 5.0 8.0
Unplanned revascularization 3.2 3.9
Major bleeding 7.3 6.3
1-year
Composite ischemia* 18.0 17.9
Death 5.0 3.6
*Death, myocardial infarction, or unplanned ischemia-driven revascularization.Abbreviations as in Tables 1 and 2.dogrel before or immediately after PCI, no differences were
pparent between those randomized to an anticoagulant plus a
P IIb/IIIa inhibitor versus bivalirudin monotherapy (Fig. 5).
mong troponin-positive patients receiving clopidogrel late
fter their PCI or not at all, the absolute difference in ischemic
vent rates between patients receiving a GP IIb/IIIa inhibitor
nd bivalirudin alone tended to be substantially greater.
nd Its Components for Patients Who Received Clopidogrel at Any Time
tor
B/A Risk Ratio
(95% CI)
Arm C
Bivalirudin Alone
(n  2,284)
%
C/A Risk Ratio
(95% CI)
1.08 (0.90–1.31)
p  0.41
8.2 0.98 (0.81–1.20)
p  0.88
1.36 (0.75–2.49)
p  0.31
1.0 1.22 (0.66–2.26)
p  0.52
1.11 (0.88–1.40)
p  0.39
6.0 1.05 (0.83–1.33)
p  0.69
1.12 (0.82–1.53)
p  0.48
2.8 0.87 (0.62–1.20)
p  0.39
1.18 (0.95–1.46)
p  0.13
3.5 0.53 (0.41–0.69)
p  0.0001
1.10 (0.97–1.25)
p  0.12
18.7 1.05 (0.93–1.19)
p  0.45
1.07 (0.77–1.49)
p  0.68
3.1 1.05 (0.75–1.46)
p  0.79
Table 1.
nd Its Components for Patients Who Received Clopidogrel >30 Min After
tor
B/A Risk Ratio
(95% CI)
Arm C
Bivalirudin Alone
(n  290)
%
C/A Risk Ratio
(95% CI)
1.40 (0.88–2.22)
p  0.16
14.1 1.66 (1.05–2.63)
p  0.03
0.63 (0.18–2.21)
p  0.47
1.7 0.91 (0.28–2.95)
p  0.88
1.59 (0.87–2.90)
p  0.13
10.3 2.05 (1.14–3.68)
p  0.02
1.23 (0.55–2.76)
p  0.62
6.6 2.08 (0.98–4.39)
p  0.06
0.86 (0.49–1.53)
p  0.61
3.4 0.48 (0.23–0.98)
p  0.04
0.99 (0.72–1.38)
p  0.97
21.7 1.21 (0.88–1.67)
p  0.25
0.71 (0.34–1.47)
p  0.35
3.1 0.61 (0.28–1.37)
p  0.23oint a
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646iscussion
his post-hoc analysis of NSTE ACS patients undergoing
CI in the ACUITY trial suggests that as long as clopi-
ogrel is administered no later than 30 min after PCI,
schemic outcomes remain similar in patients treated with
ivalirudin monotherapy or heparin plus a GP IIb/IIIa
nhibitor while a significant reduction in major bleeding is
aintained. These findings clarify the initially published
esults of the ACUITY trial, which suggested that patients
ho were randomized to bivalirudin alone and who were
ot pre-treated with clopidogrel experienced more ischemic
vents. Those initial findings were rapidly interpreted to
mply that prolonged (i.e., 6 h) pre-treatment with clopi-
ogrel was needed if bivalirudin was to be used in the NSTE
CS setting (7,8). This current, more focused, analysis of
he ACUITY trial reveals that initial findings were driven
rimarily by the results in a small number of patients who
eceived no clopidogrel or by those who first received
lopidogrel more than 30 min after PCI.
In contrast to the findings from other studies (14),
re-treatment with clopidogrel did not provide a protec-
ive effect in patients randomized to a heparin plus a GP
Ib/IIIa inhibitor in the ACUITY trial; ischemic event
ates in that treatment arm were nearly identical regard-
ess of whether patients received clopidogrel before PCI,
fter PCI, or not at all. Conversely, and more in line with
xpectations from prior studies, patients in the bivaliru-
in monotherapy or bivalirudin plus a GP IIb/IIIa
nhibitor arms experienced ischemic event rates 2 to 3
imes higher if they had not received clopidogrel than if
lopidogrel was administered pre-PCI. Because of this
pparent differential effect of clopidogrel, which may
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Figure 5. 30-Day Composite Ischemic Outcomes Among Troponin-Positive
Incidence of the 30-day composite ischemic outcome among patients who we
sus the combination of the 2 cohorts randomized to a platelet GP IIb/IIIa anta
and the timing of clopidogrel initiation among patients undergoing PCI. Abbreave in part been due to chance, direct comparison ietween the heparin plus GP IIb/IIIa inhibitor arm
ersus the bivalirudin-alone arm suggested that ischemic
vent rates were different if clopidogrel was not admin-
stered before PCI. In the present analysis, we more
horoughly explored whether a NSTE ACS patient
ndergoing a PCI without concomitant platelet inhibi-
ion with a GP IIb/IIIa inhibitor is especially dependent
n clopidogrel pre-treatment. These results suggest that
atients who received clopidogrel at any time before the
CI or within 30 min thereafter experienced similar
schemic event rates whether randomized to bivalirudin
lone or a GP IIb/IIIa antagonist plus an anticoagulant.
n the other hand, patients randomized to bivalirudin
lone consistently tended to have substantially higher
schemic event rates than did GP IIb/IIIa inhibitor-
reated patients if clopidogrel was initiated more than 30
in after the completion of PCI or not at all.
“Pre-treatment” with clopidogrel typically implies admin-
stration of a loading dose with an adequate duration of time
efore the PCI to decrease periprocedural ischemic events.
or a 300-mg loading dose, the best available data suggest
hat maximal clinical benefit occurs after as long as 15 to
4 h (13). For a 600-mg loading dose, the best available data
uggest that at least 2 h of pre-treatment is necessary (15).
hether there is any benefit of initiating clopidogrel at
inadequate” doses or duration before a PCI compared with
reatment at the time of the procedure remains unproven,
ut at least 1 analysis of a placebo-controlled, blinded trial
ould suggest there is not (13). It is important, however, to
cknowledge that in the ACUITY trial, the percentage of
atients “adequately” pre-treated was not characterized, but
s the average durations between admission and random-
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y anticoagulant
P=0.72
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ts
ponin-positive at baseline based on randomization to bivalirudin alone ver-
plus either bivalirudin or heparin (unfractionated or low-molecular-weight)
ns as in Figures 1 and 2.Clop
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647ossible that a substantial proportion of patients in this
nalysis would not be considered to have been adequately
re-treated.
Initial analyses of the ACUITY trial concentrated pri-
arily on the results of 2 of the 3 study arms, namely
ivalirudin alone versus the active control arm of heparin
lus a GP IIb/IIIa inhibitor. In this present study, we also
erformed an analysis in which patients in the 2 arms
andomized to a GP IIb/IIIa inhibitor were combined and
ompared with the 1 arm of bivalirudin alone. This second-
ry analysis was carried out to focus on whether patients not
eceiving additional antiplatelet protection beyond aspirin
ere particularly likely to benefit from the addition of
lopidogrel compared with those receiving a GP IIb/IIIa
ntagonist. Pooling of the heparin plus GP IIb/IIIa and
ivalirudin plus GP IIb/IIIa arms is justifiable for an
xploratory analysis; 30-day ischemic event rates in these 2
roups were nearly identical, and there are no prior data to
uggest or a priori reasons to believe that among patients
reated with GP IIb/IIIa inhibitors, clopidogrel treatment
ould be any more or less beneficial with bivalirudin versus
eparin. The findings of this pooled analysis were confir-
atory of those of the comparison between the heparin plus
P IIb/IIIa inhibitor versus bivalirudin-only treatments
rms.
Although it may be assumed that adding a thienopyridine
o a GP IIb/IIIa inhibitor might offer no additional benefit
ue to a lack of any further inhibition of measurable platelet
ggregation, clinical data suggest otherwise (16). Moreover,
t has been shown that in troponin-positive patients with
CS, addition of a GP IIb/IIIa inhibitor results in further
eduction in ischemic events beyond that provided by
re-treatment with a thienopyridine in combination with
igh-dose heparin (4). It is therefore reassuring that in this
resent analysis of the troponin-positive cohort in the
CUITY trial, patients randomized to bivalirudin alone
xperienced similar ischemic event rates as those random-
zed to a GP IIb/IIIa inhibitor, irrespective of whether
lopidogrel was administered before PCI or in the peripro-
edural period. This finding is important in that many
atients with an NSTE ACS are not preloaded with
lopidogrel before diagnostic angiography and can therefore
nly receive the drug just before or after completion of PCI.
An important question is whether the high event rates in
he patients who never received clopidogrel despite under-
oing a PCI were due to complications that occurred at the
ime of the procedure. Because patients who received no
lopidogrel also had no major bleeding events (data not
hown), it seems unlikely that a bleeding complication was
reason for not ever receiving clopidogrel. Only 11 of the
29 patients who received no clopidogrel underwent a
oronary artery bypass graft during their index hospitaliza-
ion; thus clopidogrel was not withheld to prevent periop-
rative bleeding in the vast majority of patients. Given the aack of information regarding reasons why clopidogrel was
ot administered after PCI, we can provide no clear
xplanation for this differential in outcomes, although it is
ossible that this finding is due to the play of chance in a
mall subgroup.
tudy limitations. The primary limitations of this analysis
re those inherent with any post-hoc, nonrandomized
nalysis. Also, as randomized therapy was not blinded, it
s possible that the investigators may have treated pa-
ients differently, including the use of adjunctive anti-
latelet therapies such as clopidogrel, based on their
iases toward the use of a GP IIb/IIIa receptor inhibitor
n the setting of PCI. Although the use of clopidogrel
nd its timing seemed to be well balanced between
reatment groups, biases based upon open-label alloca-
ion to the randomized therapies may have contributed to
ndetected imbalances in the underlying risk of patients
n the various cohorts of clopidogrel pre-treatment. Also,
atients randomized into clinical trials represent a unique
ohort of patients whose treatment does not always
eflect real-world clinical practice, including the potential
or shorter delays to PCI and therefore shorter durations
f pre-treatment. Finally, it is important to re-emphasize
hat the dose or duration of clopidogrel treatment before
he time of their PCI was unknown in the majority of
atients in the ACUITY trial, requiring estimation of
ime intervals as described in this report.
onclusions
he results of this analysis suggest that with initiation of
lopidogrel treatment before or within 30 min of the
erformance of PCI, bivalirudin has similar efficacy in
reventing short-term and long-term ischemic complica-
ions as does a GP IIb/IIIa inhibitor with UFH, enox-
parin, or bivalirudin among NSTE ACS patients, while
aintaining a significant reduction in major bleeding.
owever, among patients in whom it is anticipated that
lopidogrel will be given more than 30 min or not at all
fter PCI, an antithrombotic regimen that includes GP
Ib/IIIa inhibition may provide better protection against
schemic events than does bivalirudin alone. These data
re reassuring for the treatment of patients with NSTE
CS who undergo diagnostic catheterization with biva-
irudin alone without clopidogrel pre-loading. If a PCI is
ndicated, such patients may be treated with a clopidogrel
oading dose just before or immediately after the PCI,
ith the expectation of a similar risk of ischemic com-
lications but a lower risk of bleeding compared with the
isk of bleeding in patients treated with a GP IIb/IIIa
ntagonist.
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